The company focuses on non-fusion spinal implant technology. Its proprietary coflex Interlaminar Technology is indicated for use in one- or two-level lumbar stenosis from L1-L5 in adult patients.
In July, the company published two separate independent prospective clinical studies that examined the short-and long-term durability of coflex interlaminar stabilization.
More articles on devices:
Alphatec Spine 3Q revenue up 2%: 10 key concepts
NuVasive’s 3Q revenue up 12.3%: 10 things to know
Zimmer Biomet names new leaders
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
